AlpInvest Partners’s Acceleron Pharma XLRN Stock Holding History

AlpInvest Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-21,106	Closed	-$612K	–	9
2017 Q1	$559K	Sell	21,106 -2,166	-9%	-$57.1K	1.73%	13
2016 Q4	$594K	Buy	23,272 +13,921	+149%	+$441K	2.1%	12
2016 Q3	$338K	Hold	9,351	–	–	0.84%	13
2016 Q2	$318K	Hold	9,351	–	–	0.63%	23
2016 Q1	$247K	Hold	9,351	–	–	0.47%	27
2015 Q4	$456K	Sell	9,351 -15,843	-63%	-$570K	0.76%	23
2015 Q3	$627K	Hold	25,194	–	–	1.23%	22
2015 Q2	$797K	Buy	25,194 +8,198	+48%	+$265K	1.01%	19
2015 Q1	$647K	Sell	16,996 -4,607	-21%	-$183K	1.21%	17
2014 Q4	$842K	Buy	+21,603	New	+$753K	2.09%	9

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AlpInvest Partners's XLRN Position: Q2 2017 in Review

AlpInvest Partners sold out of Acceleron Pharma (XLRN) in Q2 2017, closing a stake of 21,106 shares — an estimated $612K sold.

AlpInvest Partners first reported a position in XLRN in Q4 2014 and held it in 10 quarters. The position peaked at $842K in Q4 2014. 128 funds tracked by Wall St. Rank hold XLRN as of Q2 2017.

AlpInvest Partners reported no remaining Acceleron Pharma position as of Q2 2017 after selling out during the quarter.
AlpInvest Partners sold 21,106 Acceleron Pharma shares in Q2 2017, an estimated $612K.
AlpInvest Partners first reported a position in Acceleron Pharma in Q4 2014 and held it in 10 quarters.
AlpInvest Partners's Acceleron Pharma position peaked at $842K in Q4 2014.
128 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2017.

Based on AlpInvest Partners's 13F filing for Q2 2017, filed 11 Aug 2017.